Aligos Therapeutics (ALGS) Short-term Investments (2019 - 2026)

Aligos Therapeutics has reported Short-term Investments for 8 years, with the latest figure at $24.9 million in Q1 2026.

• For the quarter ending Q1 2026, Short-term Investments rose 22562.73% year-over-year to $24.9 million; the trailing twelve-month figure through Mar 2026 stood at $24.9 million (up 22562.73% YoY), and the FY2025 full-year result was $59.5 million, up 198.57% from the prior year.
• Short-term Investments for Q1 2026 stood at $24.9 million, down from $59.5 million in the prior quarter.
• The five-year high for Short-term Investments was $88.6 million in Q1 2024, with the low at $10000.0 in Q2 2023.
• Historically, Short-term Investments has averaged $23.3 million across 5 years, with a median of $397000.0 in 2023.
• Annual changes were most pronounced in 2023 — Short-term Investments tumbled 99.99% — and 2025, when it jumped 51854.55%.
• Aligos Therapeutics' Short-term Investments stood at $115000.0 in 2022, then retreated by 13.04% to $100000.0 in 2023, then surged by 19842.0% to $19.9 million in 2024, then surged by 198.57% to $59.5 million in 2025, then slumped by 58.13% to $24.9 million in 2026.
• The last three Short-term Investments figures came in at $24.9 million (Q1 2026), $59.5 million (Q4 2025), and $57.2 million (Q3 2025), per Business Quant data.